年轻早期子宫内膜癌患者保留生育功能孕激素治疗期间体重变化的意义
这项多中心回顾性研究纳入154例高分化、MRI示局限于子宫内膜的子宫内膜样腺癌年轻患者,接受保留生育功能孕激素治疗。治疗期间体重变化与完全缓解、复发、妊娠及活产率均无显著关联,但治疗前和治疗后BMI≥25kg/m2是治疗反应差和高复发的显著预测因素。
要点
- 治疗期间体重变化与完全缓解、复发、妊娠及活产率无显著关联。
- 治疗前BMI≥25kg/m2与较低完全缓解率(P=0.003)和高复发率(P=0.033)显著相关。
- 治疗后BMI≥25kg/m2也是高复发率的显著因素(P=0.049)。
核心结论
- 孕激素治疗期间体重变化对完全缓解、复发、妊娠和活产率影响很小。
- 治疗前和治疗后BMI≥25kg/m2是治疗反应差和高复发的显著预测因素。
- 因此,在孕激素治疗期间维持患者正常BMI很重要。
研究设计与样本
- 多中心回顾性研究,纳入154例年轻患者,均为MRI示高分化、局限于子宫内膜的子宫内膜样腺癌,接受保留生育功能孕激素治疗。
主要发现
- 基线及孕激素治疗完成时平均体重分别为65.3±16.2kg与66.5±15.9kg(P=0.044),平均BMI分别为25.51±5.99kg/m2与25.99±5.94kg/m2(P=0.034)。
- 孕激素治疗期间,51例(33.1%)体重下降、29例(18.8%)体重无变化、74例(48.1%)体重增加,其中11例(7.1%)体重下降10%、30例(19.5%)体重增加10%。
- 治疗前BMI≥25kg/m2与较低完全缓解率(P=0.003)和高复发率(P=0.033)显著相关;治疗后BMI≥25kg/m2也是高复发率的显著因素(P=0.049)。
- 治疗期间体重变化与完全缓解或复发率无显著关联。
- 治疗前后BMI及体重变化与妊娠率和活产率无关联。
临床怎么用
- 作者认为,孕激素治疗期间维持患者正常BMI很重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the influence of body weight change during fertility-sparing progestin therapy on oncologic and reproductive outcomes in young women with early-stage endometrial cancer who did not complete child bearing. METHODS: This multicenter, retrospective study included 154 young patients with well-differentiated, endometrium-confined endometrioid endometrial adenocarcinoma on magnetic resonance imaging who received fertility-sparing progestin therapy. RESULTS: The mean body weight and body mass index (BMI) at baseline and progestin therapy completion was 65.3±16.2 and 66.5±15.9kg (P=0.044), respectively, and 25.51±5.99 and 25.99±5.94kg/m2 (P=0.034), respectively. During progestin therapy, 51 (33.1%), 29 (18.8%), and 74 patients (48.1%) had weight loss, no weight change, and weight gain, respectively, of which 11 (7.1%) had 10% weight loss and 30 (19.5%) had 10% weight gain. A pretreatment BMI of ≥25kg/m2 was significantly associated with a lower complete response rate to progestin therapy (P=0.003) and a high recurrence rate (P=0.033). A posttreatment BMI of ≥25kg/m2 was also a significant factor for high recurrence rate (P=0.049). However, weight change during therapy was not significantly associated with complete response or recurrence rate. Pre and posttreatment BMIs and weight change were not associated with pregnancy and live birth rates. CONCLUSION: Weight change during progestin therapy has little influence on complete response, recurrence, pregnancy, and live birth rates. However, pre and posttreatment BMIs of ≥25kg/m2 were significant predictors for poor treatment response and high recurrence. Therefore, it is important to maintain patients' normal BMIs during progestin therapy.
引用
- Park JY, Seong SJ, Kim TJ, et al. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. Gynecol Oncol. 2017. PMID: 28526167. doi:10.1016/j.ygyno.2017.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。